Clinical Trials

Valbenazine (NBI-98854): An investigational treatment for Tourette syndrome

ONGOING STUDIES IN TOURETTE SYNDROME

T-Forward Study

In late 2015, Neurocrine initiated a Phase 2 study of valbenazine in adults with Tourette syndrome. The T-Forward study is a randomized, double-blind, placebo-controlled, multi-dose, parallel group study of up to 90 adults. Subjects will receive once-daily dosing of valbenazine during an eight-week treatment period to assess the safety, tolerability and efficacy of valbenazine in Tourette patients. The primary endpoint of this study is the change from baseline of placebo vs. active scores utilizing the Yale Global Tic Severity Scale at the end of Week 8. Data readout from this study is expected later in 2016.

For more information on the T-Forward study visit: www.tforwardstudy.com.

T-Force GREEN Study

In early 2016, the company initiated a Phase 2 study of valbenazine in children and adolescents with Tourette syndrome. The T-Force GREEN study is a randomized, double-blind, placebo-controlled, multi-dose, parallel group, study of up to 90 children and adolescents between the ages of 6 and 17 years old. Subjects will receive once-daily dosing of valbenazine during an eight-week treatment period to assess the safety, tolerability and efficacy of valbenazine in Tourette patients. The primary endpoint of this study is the change from baseline of placebo vs. active scores utilizing the Yale Global Tic Severity Scale at the end of Week 6.

For more information on the T-Force Green study visit: www.tforcegreen.com.

To learn about our current ongoing studies, watch our videos:

CP-TS-US-0001 9/16